<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of epigenetic modification of gene expression is becoming increasingly important in how we understand the loss of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor gene function in a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> predisposing syndromes </plain></SENT>
<SENT sid="1" pm="."><plain>This review explores the importance of epimutation in <z:e sem="disease" ids="C0004903" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Beckwith-Wiedemann syndrome</z:e> and <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumour</z:e> and focuses on genomic methylation in both imprinted and non-imprinted genes as a key mechanism in the development of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>